A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions: Immune Thrombocytopenia
Age: Between 1 - 17 Years
Gender: Male or Female

Inclusion Criteria

Newly diagnosed ITP (<3 months from diagnosis (first abnormal platelet count)
Requires pharmacologic treatment from the perspective of the treating clinician.

Recruitment Status

Open

Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required

* Your Email

* First Name

Last Name

* Your Phone

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Recruitment Status

Open

A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

Are you eligible to participate in this study?

Recruitment Status

Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required

Recruitment Status

Volunteer Registry

Contact Us

A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

Are you eligible to participate in this study?

Recruitment Status

Contact the research team to learn more about this study. Fields marked with asterisk (*) are required

Recruitment Status

Volunteer Registry

Contact Us

Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required